📻Ya están sonando los Cowboys de Medianoche en esRadio
Que disfrutéis el programa y que tengáis un gran fin de semana 🍸
Foto; JEOSM #thetrueshoot

Certainly confounders here, but interesting look at immediate vs deferred systemic therapy in pts with pleural mesothelioma Clinical Lung Cancer. In this group, 58% of deferred pts eventually had systemic therapy. OS longer in deferred group (20.6m vs 11.5m).

clinical-lung-cancer.com/article/S1525-…

Neoadjuvant platinum-based ICI-chemotherapy for patients with early-stage NSCLC is associated with improvements in 2-year event-free survival and pathologic complete response, finds systematic review and meta-analysis. ja.ma/3Q0UCwo

🧬🧪Have you ever identify a potential germline alteration in the results of a liquid biopsy?

Check out our latest review about incidental PGV, now published in British Journal of Cancer

bit.ly/43R0i1J

Laura Mezquita
Hospital Clínic
International Society of Liquid Biopsy

Should we pursue upfront radiation / local therapy for brain metastases in pts with #EGFR NSCLC? Concerns about toxicity, radiation necrosis. But retrospective study Lung Cancer Journal shows OS and CNS-PFS favor upfront local therapy. Is it time for a trial?

lungcancerjournal.info/article/S0169-…

Multicenter analysis of long-term survivors of metastatic #EGFR NSCLC in #JTOCRR JTO & JTO CRR. Comparing ≥5y survivors (n=133) and <5y (n=127), similar rate of TP53 and PIK3CA comutations. Brain metastases at any point associated with worse survival.

jtocrr.org/article/S2666-…

Long-term follow up from phase II study of pembrolizumab x 1y after ablation for #oligometastatic NSCLC in #JTOCRR . mPFS 19.7m, mOS not reached, 5y OS rate 60%, better OS with metachronous oligometastases. JTO & JTO CRR

jtocrr.org/article/S2666-…

⭐️Just published in time for the #ELCC24 👉The Impact of Prior Single-Gene Testing(SGT) on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
👉For patients with NSCLC, initial use of SGT increases subsequent CGP test cancellations, turnaround…

Systematic review of TKI efficacy in NSCLC harboring uncommon EGFR mutations JTO & JTO CRR:

- 1836pts, 38 studies
- G719X, S768I, E709X, L747X; compound mtns; & PACC mtns: best ORR to 2nd-gen TKIs
- L861Q best ORR to 3rd gen TKI

Alfredo Addeo MD OncoAlert #LCSM

jto.org/article/S1556-…

🌍Pumped to share that our article “Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology” is now out in TAMO!
bit.ly/48XLEXo

Laura Mezquita
Miguel García

Key findings below

Global representation and research is key to unravel the role of carcinogens and lung cancer molecular subtypes. Thank you @j.jlaguna Miguel García & Laura Mezquita for leading this review & all co-authors for this collaborative endeavor.

Happy to share our work in ctDNA in HNSCC - The PRE-MERIDIAN study. We evaluated difference ctDNA approaches to detect MRD in HNSCC. Thanks to Conquer Cancer, the ASCO Foundation YIA for the support in this project! nature.com/articles/s4141…

Finally happy to share our paper at Cancer Discovery tracking fragmentomics and methylation in plasma to predict IO outcomes. Great summary of my friend and first co-author Eric Stutheit-Zhao! Thanks to all the co-authors and specially to our senior authors Pugh Lab and Lillian Siu!

Review on cardiotoxicity from #EGFR TKIs in Clinical Lung Cancer. QT prolongation seen in 0-11% of trials (0-27.8% in observational studies) but no torsades de pointes. Heart failure seen in 0-8% of pts. Safe profile, but watch for drug-drug interactions.

clinical-lung-cancer.com/article/S1525-…

Out now on Annals of Oncology our editorial on the potential role of ctDNA in resectable NSCLC undergoing neo-adj chemo. Important clinical data that can provide a guide for future studies in the era of neo-adj chemo-IO. Christian Rolfo International Society of Liquid Biopsy sciencedirect.com/science/articl…

APPLE Trial 🍎🍏 doi.org/10.1200/JCO.23…
Thanks a lot Rafal Dziadziuszko, Benjamin Besse for giving me the opportunity and for trusting me, and EORTC , all authors for helping in this “adventure” started almost 10 years ago. THANKS

La supervivencia del cáncer en España se ha DUPLICADO en los últimos 40 años.
Esa debe ser la noticia de este lunes 29 de enero.
SEOM

✅ En el #SimposioBiopsiaLíquida , el dr. Miguel García divulga los resultados de un proyecto de investigación canadiense que ha demostrado el beneficio de esta técnica para el genotipado molecular ligado al diagnóstico en pacientes con sospecha de cáncer de pulmón avanzado.

We’ll start 2024 with this ttx algorithm for NSCLC🫁including non-metastatic NSCLC
Pending Qx💡:
✏️Will ADC overcome docetaxel? 📛
✏️ADC 2n L for oncogenic-driven? 🎉
✏️Perioperative vs Induction?🥊
✏️Adjuvant RET TKI?🧬
✏️Academic trials for ↗️ / ↘️ ttx
And more!! @oncoalert

Las oncólogas que han creado una escuela para enseñar a vivir con cáncer
elpais.com/sociedad/la-su…